Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 3/20 | 0.56 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.56 |
| ▸ | ITGAL | P20701 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | GGT1 | P19440 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28327021 | 0.87 | ITGB2 (0.60) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL22608036 | 0.85 | ITGB2 (0.56) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL22608018 | 0.82 | ITGB2 (0.58) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL28386295 | 0.82 | ITGB2 (0.60) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL22607987 | 0.81 | ITGB2 (0.58) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL30081493 | 0.80 | SLC15A2 (0.72) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL2197786 | 0.80 | SLC15A2 (0.72) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL5494124 | 0.80 | ITGB2 (0.61) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL14952736 | 0.80 | ITGB2 (0.61) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL27413426 | 0.80 | ITGB2 (0.67) | ITGB2ICAM1ITGALCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361875-A1 | PEPTIDE DERIVATIVES AND THERAPEUTIC ACTIVITY THEREOF | FLAMMA S.P.A. (IT) | 2020-11-19 | — | — | US | claimed |
| EP-3732165-A1 | PEPTIDE DERIVATIVES AND THERAPEUTIC ACTIVITY THEREOF | Flamma S.P.A. (IT) | 2020-11-04 | — | — | EP | claimed |
| US-11420943-B2 | Peptide derivatives and therapeutic activity thereof | FLAMMA S.P.A. (IT) | 2022-08-23 | — | — | US | disclosed |
| EP-3732165-B1 | PEPTIDE DERIVATIVES AND THERAPEUTIC ACTIVITY THEREOF | FLAMMA SPA (IT) | 2022-08-17 | — | — | EP | disclosed |
| US-20200361875-A1 | PEPTIDE DERIVATIVES AND THERAPEUTIC ACTIVITY THEREOF | FLAMMA S.P.A. (IT) | 2020-11-19 | — | — | US | disclosed |
| EP-3732165-A1 | PEPTIDE DERIVATIVES AND THERAPEUTIC ACTIVITY THEREOF | Flamma S.P.A. (IT) | 2020-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361875-A1 | PEPTIDE DERIVATIVES AND THERAPEUTIC ACTIVITY THEREOF | GPX4, VIP, GPX1 | ITGB2 2785/4885ICAM1 973/4885ITGAL 2302/4885 |
| US-11420943-B2 | Peptide derivatives and therapeutic activity thereof | GPX4, VIP, GPX1 | ITGB2 2785/4885ICAM1 973/4885ITGAL 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.